FAQ: What is The Role of IL23/IL17 Axis in Rheumatic Disease

Join Katie Springer, PA-C, from Northwestern Medicine in Lake Forest, Illinois, as she explores the critical role of the IL-23/IL-17 axis in immune-mediated inflammatory diseases, including psoriatic arthritis and psoriasis.This session provides a comprehensive look at how IL-23 and IL-17 contribute to the pathogenesis of autoimmune conditions, driving chronic inflammation in the skin, joints, and entheses. Understanding the IL-23/IL-17 pathway is key to optimizing targeted therapies for autoimmune disease management.IL-23 is a pro-inflammatory cytokine produced by dendritic cells and macrophages, stimulating TH17 cell differentiation and leading to IL-17A and IL-17F production. This, in turn, drives neutrophil recruitment and tissue inflammation. Dysregulation of this pathway results in immune activation, leading to the inflammatory plaques seen in psoriasis, joint inflammation in psoriatic arthritis, and enthesitis. Additionally, IL-17 induces the production of other pro-inflammatory mediators such as IL-1β, IL-6, and TNF-α, further amplifying the inflammatory cascade and contributing to disease progression.This educational session is essential for rheumatology APPs, clinicians, and healthcare professionals seeking to enhance their understanding of targeted immunotherapy.Want to learn more? Visit the RhAPP website or access exclusive educational content on the RhAPP ACE App.